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Abstract
Background: There is renewed interest in magnetic hyperthermia as a treatment modality for cancer, especially
when it is combined with other more traditional therapeutic approaches, such as the co-delivery of anticancer
drugs or photodynamic therapy.
Methods: The influence of bimagnetic nanoparticles (MNPs) combined with short external alternating magnetic
field (AMF) exposure on the growth of subcutaneous mouse melanomas (B16-F10) was evaluated. Bimagnetic Fe/
Fe3O4 core/shell nanoparticles were designed for cancer targeting after intratumoral or intravenous administration.
Their inorganic center was protected against rapid biocorrosion by organic dopamine-oligoethylene glycol ligands.
TCPP (4-tetracarboxyphenyl porphyrin) units were attached to the dopamine-oligoethylene glycol ligands.
Results: The magnetic hyperthermia results obtained after intratumoral injection indicated that micromolar
concentrations of iron given within the modified core-shell Fe/Fe3O4 nanoparticles caused a significant anti-tumor
effect on murine B16-F10 melanoma with three short 10-minute AMF exposures. We also observed a decrease in
tumor size after intravenous administration of the MNPs followed by three consecutive days of AMF exposure
24 hrs after the MNPs injection.
Conclusions: These results indicate that intratumoral administration of surface modified MNPs can attenuate
mouse melanoma after AMF exposure. Moreover, we have found that after intravenous administration of
micromolar concentrations, these MNPs are capable of causing an anti-tumor effect in a mouse melanoma model
after only a short AMF exposure time. This is a clear improvement to state of the art.
Background
Recently, questions have emerged regarding whether
anticancer drug development is headed in the right
direction and whether opportunities that are off the
accepted path are being overlooked [1]. Largely due to
the increasing insight into the series of mutations asso-
ciated with the development of cancer, drug develop-
ment has moved into the “molecular target” area. There
have been initial successes (e.g. imatinib mesylate for
the treatment of chronic myelogenous leukemia and
gastrointestinal stromal tumors); however, the genetic
complexity and diversity of tumor cells, including the
occurrence of cancer stem cells, have prevented molecu-
lar targeting from becoming universally successful.
Because the progression of a normal cell to a cancer cell
involves numerous genetic mutations, targeting one or
even several gene products may be ineffective. Further-
more, many biological processes feature alternate path-
ways which can be upregulated, if needed, thus
thwarting molecularly targeted therapies [1]. To over-
come these obstacles, a successful cancer therapy has to
combine several approaches. Molecular targeting can be
a viable component of this methodology. However,
other approaches, such as stem cell delivery, hyperthermia,
photodynamic therapy, and the design of multifunctional
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(theranostics) have not received full attention during the
last decade.
We and others are working toward cost-effective treat-
ment methods based on non-conventional combinations
of known and proven techniques. We asked whether it
is possible to achieve cancer localization by using por-
phyrin labels for the delivery of iron-containing super-
paramagnetic nanoparticles to tumor tissue. Tumor cells
selectively uptake porphyrins, which they need as pros-
thetic groups in their elevated sugar metabolism, via
over-expression of porphyrin receptors in their cell
membranes [2]. There is a strong positive correlation
between the cell uptake of a variety of chemically
defined, synthetic and natural porphyrins and their octa-
nol/water distribution coefficients [3,4]. These findings
support the paradigm that there indeed exists a por-
phyrin uptake mechanism other than endocytosis in
cancer cells. The LDL (lowdensity lipoprotein) receptor,
which is over-expressed in cancer cells, has the ability to
take up porphyrins as well, either alone or simulta-
neously with other porphyrin receptors. Localized
hyperthermia is a powerful therapeutic modality. When
administered selectively, hyperthermia treatment can be
very potent against many types of cancer because it is
not based on the intake of drugs by cancer cells, but on
the application of heat. When heated to 45°C, vital pro-
teins of the cancer cell become damaged (e.g. misfolded)
and/or the cell membrane partially dissolves in the sur-
rounding aqueous medium [5]. A multitude of heat-
induced deviations from the “normal” metabolism of a
cancer cell can eventually lead to apoptosis (pro-
grammed cell death). Although many cancer types are
slightly more susceptible to hyperthermia than healthy
cells, the latter essentially share the same fate when
heated [6]. Therefore, the development of methods to
localize hyperthermia to cancer cells remains one of the
challenges in this field. This is important when attempt-
ing to treat solid tumors within the human body as well
as for treatment of metastasizing cancers. The use of
tethered porphyrins as “bait” may provide an effective
(and low cost) alternative to using antibodies for getting
magnetic nanoparticles effectively into tumors, which is
currently a common tumor targeting method.
Magnetic nanoparticles dump thermal energy into the
system, therefore providing heating (magnetic
hyperthermia) [7]. Heating takes place by power absorp-
tion of magnetic particles due to an A/C magnetic field
[8]. The important factor for magnetic heating experi-
ments is the specific absorption rate (SAR), which is
determined by SAR = C × ΔT/Δt, where C is the speci-
fic heat capacity of the sample and T and t are the tem-
perature and time, respectively. SAR is very sensitive to
the material properties. While in multi-domain particles
the dominant heating is hysteresis loss due to the move-
ment of domain walls, this is not the case with small,
single domain particles. The two main contributing
mechanisms of SAR in single domain magnetic NPs are
the Brownian (rotation of the entire nanoparticle) and
Néel (random flipping of the spin without rotation of
the particle) relaxations [9,10]. The transition between
the two mechanisms occurs between 5-12 nm for var-
ious materials, but it also varies with frequency [11]
Melanoma incidence has reached almost epidemic
proportions worldwide. When it is present as dissemi-
nated metastatic disease it is not curable using current
clinical tools; traditional chemotherapy is often ineffec-
tive due to inherent drug resistance [12]. We have
selected the B16-F10 melanoma model in syngeneic
C57BL/6 female mice because this type of melanoma
has proven to be quite resistant to treatment. In order
to evaluate the efficacy of hyperthermia treatment
against cancer, we did not want to select a less resistant
cancer cell line/host system. In addition, since
hyperthermia often enhances the immune response, an
immunocompetent host was desirable.
In the work reported here, we have used (bi)magnetic
iron/iron oxide core/shell nanoparticles, synthesized by
NanoScale Corporation (Manhattan, KS), for A/C (alter-
nating current)-magnetic cancer therapy, because they
exhibit superior properties in several areas: The nano-
scopic size (d<15 nm) of the stealth-protected Fe/Fe3O4
core/shell nanoparticles will permit passive tumor tar-
geting from the bloodstream by using the EPR
(enhanced permeation and retention) effect [13,14]. In
addition, we surmise that our porphyrin coating may
enhance MNP uptake in tumors, because cancer cells
are in constant need of porphyrins as prosthetic groups
in their elevated sugar metabolism [2] and overexpress
the LDL(low-density lipoprotein) receptor. This remains
an area for future clarification. Here, we compared the
effects of intratumoral (IT) and intravenous (IV) core/
shell porphyrin-tethered nanoparticle treatment followed
by A/C exposure on B16-F10 melanoma growth in a
mouse model.
Methods
Cell lines and animals
B16-F10 melanoma cells were purchased from ATCC
(Manassas, VA) and maintained in DMEM (Dulbecco’s
Modified Eagle Medium) supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin-streptomycin in a
humidified 37°C incubator at 5% CO2.
6-8 week old female C57/BL6 mice were purchased
from Charles River Laboratories (Wilmington, MA).
Mice were maintained according to approved institu-
tional IACUC guidelines in the Comparative Medicine
Group Facility of Kansas State University. All animal
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guidelines.
Transmission Electron Microscopy
The sizes of the different nanoparticles were determined
by using TEM. This was achieved employing a Philips
CM-200 TEM instrument operating at 100 kV. 1-2
micrograms of the MNPs were dissolved in anhydrous
tetrahydrofuran THF (5 mL) and one drop of the result-
ing nanoparticle solution was spread over a copper grid
(300 mesh size) supporting a thin film of amorphous
carbon. To reduce the damage from the electron beam,
the sample was cooled to liquid nitrogen temperature
during data collection.
Porphyrin-tethered Stealth-Coated (Bi) Magnetic
Fe/Fe3O4 Nanoparticles
The synthesis of the stealth-coated dopamine-labeled
Fe/Fe3O4 nanoparticles featuring tethered 4-tetracarbox-
yphenyl porphyrins (TCPP) is reported in a separate
publication (Wang et al., ACS Nano, 2010, in prepara-
tion). Briefly, Fe/Fe3O4-core/shell nanoparticles were
synthesized by NanoScale Corporation and then coated
with dopamine-anchored ligands. The structure of the
nanoparticles is shown in Figure 1, and results from
electron microscopy are shown in Figure 2. The dia-
meter of the Fe(0)- core was 5.4 ± 1.1 nm; the diameter
of the inorganic Fe/Fe3O4-nanoparticles was determined
to be 7.2 ± 2.8 nm. Using the program IMAGE (NIH),
we have determined the polydispersity index of the Fe/
Fe3O4-nanoparticles to be 1.31. Note that the stealth
ligand has a length of 2.5 nm (AM1-Chemdraw Ultra
3D package, Cambridge Soft Corporation, Cambridge,
MA 02140), so that the resulting bimagnetic nanoparti-
cles are 12 ± 3 nm in size. The porphyrin-labels have a
diameter of 1.95 nm (AM1). Note that the dopamine-
anchored tetraethylene glycol ligand (I) and the TCPP-
linked dopamineanchored tetraethylene glycol ligand (II)
have been synthesized separately. The binding of the
ligands to the Fe3O4 layer was achieved in anhydrous
THF under argon; the molar ratio of ligands I/II was
100/4. The reaction procedure is described in detail in a
separate paper (Wang et al., ACS Nano, 2010, in pre-
paration). We assume a statistical distribution of the
ligands at the Fe3O4 surface. Assuming a Poisson distri-
bution, 96.4 percent of the Fe/Fe3O4 NPs at the chosen
ratio feature at least one chemically linked TCPP unit,
which will act as “bait” f o rt h eB 1 6 - F 1 0c a n c e rc e l l s .
The solubility of the organically coated Fe/Fe3O4 NPs
was determined to be 0.35 mg ml
-1 and the Specific
Adsorption Rate (SAR) at the field conditions described
here was 64 ± 2 Wg
-1 (Fe).
Determination of iron concentration in MNPs
Iron concentration in MNPs was measured using the
Ferrozine-based spectrophotometric iron estimation
method [15]. For this method, 50 μlo fM N P sw e r e
diluted to 1 ml with distilled water. MNPs were then
lysed by incubating for 2 hours at 65-70°C after the
addition of 0.5 ml of 1.2 M HCl and 0.2 ml of 2 M
ascorbic acid. After incubation, 0.2 ml of reagent con-
taining 6.5 mM Ferrozine, 13.1 mM neocuproine, 2 M
ascorbic acid, and 5 M ammonium acetate was added
and incubated for 30 minutes at room temperature.
Figure 1 Composition of the 4-tetracarboxyphenyl porphyrin (TCPP)-labeled, dopamine-anchored tetraethylene glycol ligands.
Nanoparticles of 7.2 nm (outer diameter) require approximately 120 dopamine-anchored ligands (assuming a monolayer).
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measured using a UV-VIS spectrophotometer at 562
nm. A standard curve was prepared using 0, 0.1, 0.2,
0.5, 1, 2, 5 μg/ml ferrous ammonium sulfate samples.
Water with all other reagents is used as blank.
Magnetic Heating
The nanoparticles used in these experiments are domi-
nated by Néel relaxation due to the superparamagnetic
nature of the iron(0) cores. The hyperthermia apparatus
(Superior Induction Company, Pasadena, CA) used here
has a “heavy duty” induction heater converted to allow
measurement of the temperature change of a sample. In
the setup, a remote fiber optic probe (Neoptix, Quebec,
Canada) is used to monitor the temperature change.
The frequency is fixed (366 kHz, sine wave pattern);
field amplitude is 5 kA/m. The coil diameter is 1 inch, 4
turns continuously water cooled. For all in vivo experi-
ments, the mice were placed into the induction coil
using a specially designed Teflon supporter so that
tumors were located exactly in the region of the AMF
possessing the highest field density.
Cytotoxicity of Magnetic Nanoparticles on B16-F10 cells
Potential cytotoxic effects of MNPs were studied by
incubating cells in differing concentrations of MNPs.
B16-F10 cells were incubated overnight with MNPs
amounts corresponding to 5, 10, 15, 20, and 25 μg/mL
iron. After incubation, the medium was removed and
the cells were washed twice with DMEM and cells were
counted via hemocytometer with Trypan blue staining.
This method also allows counting non-viable cells since
only they allow the blue stain into the cell. All experi-
ments were run in triplicate and repeated at least twice.
Temperature measurements on mice
MNPs containing 100 μgo fi r o ni n1 0 0μlo fd i s t i l l e d
water were injected into the rear limb muscle of one
mouse and the leg was then exposed to AMF for
10 min. An optical temperature probe was inserted
intramuscularly at the injection site and the temperature
increase was measured during AMF exposure. At the
same time, the body temperature was monitored with a
separate temperature probe.
Intratumoral Hyperthermia
Ten mice were transplanted subcutaneously into each
rear limb above the stifle with 1 × 10
6 B16-F10 mela-
noma cells suspended in PBS. 120 μL of saline were
injected into melanomas on the left leg of all mice and
120 μl MNPs containing 1 mg Fe/mL were injected into
right leg tumors of all mice in three injections on day 4,
5, 6 (total of 360 μg iron). Because the MNPs were
dilute and tumor volumes were quite small, 3 injections
instead of 1 were needed in order to reach this level of
MNPs. Both left (saline) and right (MNPs) leg tumors of
f i v eo ft h em i c ew e r ee x p o s e dt oA M Ff o r1 0m i n u t e s
soon after injections. Tumors on the remaining five
mice were not exposed to AMF. Based on this, there
were 4 groups which tested the effects of MNPs with
and without AMF and of AMF alone: Group 1: Intratu-
moral saline injection, not exposed to AMF (left legs of
first five mice); Group 2: Intratumoral injection of sal-
ine, exposed to AMF (left legs of remaining five mice);
Group 3: Intratumoral injection of MNPs, not exposed
to AMF (right legs of first five mice); Group 4: Intratu-
moral injection of MNP, exposed to AMF (right legs of
remaining five mice). After three AMF exposures, tumor
sizes were measured with a caliper on days 8 to 14, and
tumor volume was calculated using the formula 0.5aXb
2
(a = longest diameter; b = smaller diameter). After 14
days mice were euthanized, tumors were excised, and
tumor weights were measured.
Intravenous administration of MNPs with AMF exposure
On day 0, 0.35 × 10
6 B16-F10 melanoma cells were
injected subcutaneously into the right legs of 27 mice.
Mice were randomly divided into three groups: Group
1, IV MNPs, no AMF; Group II, IV MNPs, AMF; Group
III, DMEM control, no AMF. On days 6, 9, and 11 after
tumor cell transplant, MNPs corresponding to 226 mcg
of iron were injected intravenously into each mouse in
Figure 2 TEM image of Fe/Fe3O4 core/shell nanoparticles
featuring an organic protective dopamine-anchored stealth
layer.
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intravenously into group III. For group II, tumors were
exposed to AMF for 10 minutes one day after each I.V.
MNPs injection (total of three AMF treatments). MNPs
not coated with porphyrins were not sufficiently soluble
in water, so we were not able to use them as control.
Tumor sizes were measured using a caliper on days 14
and 18, and tumor volume was calculated as described
above. On day 18 all mice were euthanized, tumors
were excised, and tumor weights were measured.
Histological Analysis
After euthanizing mice, lung, liver, and tumors were col-
lected and snap frozen. 8-10 μm sections were made in
a cryostat (Leitz Kryostat 1720). Staining for iron con-
tent on these sections was carried out by using Perl’s
Prussian blue staining kit (Polysciences, Inc., Warring-
ton, PA). Apoptosis was evaluated using a DeadEnd
Fluorometric TUNEL kit. (Promega Corp., Madison,
WI) following the manufacturer’s instructions.
Statistical analysis
Statistical analyses were performed by Macanova 4.12
(School of Statistics, University of Minnesota, Minnea-
polis, MN). The means of the experimental groups were
evaluated to confirm that they met the normality
assumption. To evaluate the significance of overall dif-
ferences in tumor volumes and tumor weights between
all in vivo groups, statistical analysis was performed by
analysis of variance (ANOVA). A p-value less than 0.1
was considered as significant. Following significant
ANOVA, post hoc analysis using least significance dif-
ference (LSD) was used for multiple comparisons. Sig-
nificance for post hoc testing was set at p < 0.1. All the
tumor volumes and weight data were represented as
mean +/- standard error (SE) on graphs.
Results
Cytotoxicity of Magnetic Nanoparticles on B16-F10 cells
MNP toxicity was tested after overnight incubation of
B16-F10 cell cultures in 24-well plates with various
MNPs concentrations, as measured by iron concentra-
tion. There was a dose-dependent cytotoxicity of the
MNPs. B16-F10 cancer cell viability assessment in the
presence of varying concentrations of MNPs is shown in
Figure 3. The MNPs showed a pronounced cytotoxic
effect on B16-F10 cells at >10 μg iron levels. (p-value <
0.05)
Temperature measurements on mice after
intramuscular MNPs injection
We observed 11°C temperature increase subcutaneously
at the MNPs injection site within 10 minutes of AMF
exposure. There was no increase in core body
temperature (Figure 4). These data demonstrate specific
magnetic hyperthermia. However, we did not directly
measure temperature change in tumors during experi-
ments because the necessary skin opening for the probe
caused leakage of the gelatinous melanoma tumor par-
enchyma, introducing increased potential variability in
tumor volumes.
Intratumoral Magnetic Hyperthermia
After three AMF exposures, tumor sizes were measured
from days 8 to 14; the comparison is shown in Figure 5.
We identified decreased tumor size both in tumor-bear-
ing mice treated with MNPs and with MNPs+AMF. The
tumors with MNPs+AMF showed a significant reduction
i nt u m o rv o l u m ea t8 ,9 ,1 1 ,&1 4d a y s( p<0 . 1 )c o m -
pared to the saline treated group. A decrease in size
Figure 3 In vitro cell viability of B16-F10’s cultured in medium
containing increasing concentrations of MNPs, as measured by
iron concentration. *Statistically significant (pvalue less than 0.05).
Figure 4 Graph depicting temperature change at MNP
injection site and in body core during AMF exposure,
measured with a fiber optic temperature probe.
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ine controls was also noted; however, this decrease was
not significant. Since earlier intramuscular injections
and optical probe measurements revealed hyperthermia
after AMF, the probable cause for the tumor attenuation
shown here is local hyperthermia.
Intravenously administered MNPs and AMF exposure
Tumor-bearing mice with intravenously injected MNPs
were exposed to AMF treatments three times and after
18 days were euthanized. Tumor weights were obtained
and compared to controls (Figure 6). A significant
decrease in tumor weight (p < 0.1) was observed in the
intravenous MNPs+AMF group and was most likely due
to heat generated from MNPs in tumors, based on ear-
lier optical probe experiments in anesthetized mice.
Some tumor weight decrease was also observed in intra-
venous MNPs without AMF treatment. On days 14 and
18, tumor volumes were recorded and were markedly
attenuated in the mice with MNPs with AMF; however
this was not significant (Additional file 1). After tumors
were harvested and sectioned, MNPs in tumor sections
and other tissues were identified as Prussian blue posi-
tive material in tumor bearing mice intravenously
injected with MNPs (Figure 7A-D).
Apoptosis assay
Histological analysis after apoptosis assay with the modi-
fied TUNEL assay showed the most apoptotic positive
cells in the intratumoral MNP+AMF treatments (Figure
7G), intermediate apoptosis levels in mice that received
intravenous MNP+AMF (Figure 7F), and the fewest
apoptotic cells in the saline+AMF group (Figure 7E).
Discussion
The major finding of this study was that there is a sig-
nificant decrease in tumor size after systemic (intrave-
nous) administration of low (microgram iron content)
amounts of the porphyrin-tethered MNPs and AMF
exposure compared to tumors in animals given intrave-
nous DMEM. We have found the MNPs in the melano-
mas, leading us to surmise that the porphyrins attached
to them may facilitate MNP uptake. However, further
studies are needed to confirm the porphyrin-facilitated
MNP uptake in tumors. As already discussed, cancer
cells over-express porphyrin receptors, because they
r e q u i r em o r ep o r p h y r i n sa sp r o s t h e t i cg r o u p si nt h e i r
elevated sugar metabolism than normal cells [2]. Tumor
localization of MNPs by urokinase plasminogen activa-
tor receptor (uPAR) is reported by Yang et al. [16].
Our intratumoral magnetic hyperthermia results
showed that microgram amounts of iron delivered by
the core-shell Fe/Fe3O
4 nanoparticles caused an antitu-
mor effect on melanoma with short-time AMF expo-
sures (10 min.). This is a clear improvement with
respect to current protocols, which are defined by milli-
gram amounts of MNPs and much longer exposure
times, usually 30 minutes [17]. We have also observed a
trend toward decreased tumor size after MNP adminis-
tration without AMF exposure. This is not surprising,
since our in vitro work indicated that the MNPs have a
pronounced cytotoxic effect on B16-F10 cells. In in vitro
studies, we used a total of 10 μg of ironcontaining MNP
(in 1 ml of medium) for 500,000 cells. So theoretically,
each cell is exposed to 0.00002 μg of iron. However,
in vivo, a detectable, three-dimensional tumor contains
Figure 5 Effect on tumor burden of intratumoral injection of
MNPs followed by alternating magnetic field (AMF) treatments.
Graph depicting average tumor volumes over time of B16-F10
tumor bearing mice which were later injected with either saline or
MNP intratumorally and with or without AMF treatments.
*Statistically significant (pvalue less than 0.1).
Figure 6 Effect of intravenous injection of MNP and AMF on
tumor weight. *Statistically significant difference (p-value less than
0.1) between control and IV MNP+AMF groups.
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vastly different microenvironment than the monolayer
of cells. A tumor volume of 1 cm
3 contains approxi-
mately 10
9 cells [18]. In the in vivo studies, we injected
a total of 360 μg of ironcontaining MNPs intratumorally
when mean tumor size was about 50 mm
3 (an estimated
50 million cells). Extrapolating our in vitro results,
1000 μg of iron-containing MNPs would be required for
similar toxicity to 50 million cells. Therefore, we feel that
the effective amount of core/shell MNPs in the tumor on
a per cell basis was actually much less than in the in vitro
studies. Minamimura et al. gave intratumoral iron oxide
MNP injections and noted that their MNPs alone exerted
a noticeable anti-melanoma effect [19]. In the study
reported here, the effect of MNPs alone is most probably
due to the biocorrosion of the MNPs and the subsequent
release of iron(II) and iron(III) cations, which is known
to cause cell damage via iron(II/III)-enhanced chemistry
of reactive oxygen species (ROS) [20]. Thus, we propose
a two-pronged effect: magnetic hyperthermia and the
additional generation of free radicals by manifold Fen-
ton-type reactions [20].
It must be noted that we have found significant
amounts of iron in lungs and liver, as indicated by Prus-
sian blue staining (Figure. 7B and 7C). Despite this
widespread distribution of MNPs in vivo,w ee m p h a s i z e
that there were no fatalities due to the blocking of
arteries or exposure to AMF. This may be because
the AMF was only applied to the melanoma region,
preventing unwanted hyperthermia in other tissues. Our
findings of minimal side effects after systemic adminis-
tration of MNPs are corroborated by other work testing
superparamagnetic NP for MRI capability and possible
toxic effects. Wiegand et al. showed that 250 or 500 nm
ferrofluid given intravenously to normal rabbits resulted
in normal serum iron and enzymes for liver and kidney
function at 1-72 hours after administration [21]. Kim
et al. showed that silica over coated magnetic nanoparti-
cles of 50 nm size did not cause apparent toxicity or
alter the blood-brain barrier in mice after four weeks
[22]. Pharmacokinetic data of the dependence of iron or
iron oxide nanoparticles on their respective sizes are
not yet available. Therefore, we have to rely on the avail-
able data on the distribution of stealthcoated Au-NPs
(sizes: 15 nm, 50 nm and 160 nm) in rats and rabbits
[23]. The larger the diameter of the Au-NPs, the higher
their concentration in liver and spleen 24 h after
IV-injection. The smallest Au-NPs did more evenly dis-
tribute within the mammalian bodies. Furthermore,
they remained in the bloodstream distinctly longer.
A longer residence time of our stealth Fe/Fe3O4 nano-
particles (diameter including the stealth ligands: 12 ±
3 nm) in the bloodstream may enhance the EPR effect
(enhanced permeation and retention).
Conclusion
The findings reported here indicate that ligand modified
nanoparticles given systemically or intratumorally at low
Figure 7 Prussian blue staining and evaluation of apoptosis of tissues after the in vivo experiment. Green fluorescence indicates
apoptosis positive and blue is DAPI counterstaining (E-G). A-C: IV MNP + AMF in tumor, lung, and liver, respectively. D: Intratumoral MNP, tumor
section. E-G: Apoptosis assay pictures. E: Control tumor section. F: Tumor section with intravenous MNP administration followed by AMF. G:
Tumor section with intratumoral MNP administration followed by AMF. (Scale bar = 100 μm) Additional file 1 Title: Tumor volume measurements
on day14 and 18 of intravenously administered MNPs and AMF exposure experiment. Description: Day 14 and 18 tumor volumes of individual
groups are compared. (not significant)
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B16-F10 tumors in mice after repetitive short AMF
exposure. Hence, it may be possible to exploit upregu-
lated porphyrin uptake by cancer cells to facilitate get-
ting core/shell bimagnetic nanoparticles to them, but
further work is required to confirm this. After exposure
to an AMF, which itself causes no harm, localized
hyperthermia of cancer tissue attenuates the tumor with-
out the undesirable side effects associated with traditional
chemotherapy. This approach also circumvents failure of
molecularly-targeted approaches due to redundant sys-
tems and failure of chemotherapeutic approaches due to
cancer cell multidrug resistance. Furthermore, we sur-
mise that AMF treatment is augmented by the release of
iron within the tumor regions due to biocorrosion,
increasing the intratumoral concentration of reactive
oxygen species. Thus, localized hyperthermia after sys-
temic administration of porphyrin labeled stealth MNPs
may hold promise for future clinical therapy of melano-
mas. Our future goals are to further modify the MNPs to
improve accumulation in tumors relative to other tissues
and organs, and to test these improved MNPs in treat-
ment of a preclinical metastatic model.
Additional file 1: Tumor volume measurements on day14 and 18 of
intravenously administered MNPs and AMF exposure experiment.
Day 14 and 18 tumor volumes of individual groups are compared. (not
significant).
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